{"date":"2026-02-07","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4743-2026-02-07-1133-x6cjdj","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2026-02-07","time":"11:33:50","subject":"合一ON101乳膏有效促進原發性血小板增多症相關足趾潰瘍癒合，研究成果發表於國際 SCI 期刊 Journal of Wound Care","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合一（4743），2026-02-07 11:33，「合一ON101乳膏有效促進原發性血小板增多症相關足趾潰瘍癒合，研究成果發表於國際 SCI 期刊 Journal of W」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7876-2026-02-07-0800-yshr2i","company_id":"7876","company":"鼎晉生技","market":"興櫃","industry":"生技醫療","date":"2026-02-07","time":"08:00:36","subject":"本公司OBI-858新型肉毒桿菌素獲得美國FDA核准進行醫美二期人體臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：鼎晉生技（7876），2026-02-07 08:00，「本公司OBI-858新型肉毒桿菌素獲得美國FDA核准進行醫美二期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}